Minerva Neurosciences logo
View printer-friendly version << Back
October 29, 2015

Minerva Neurosciences to Report Third Quarter 2015 Financial Results and Host Conference Call on November 5, 2015

WALTHAM, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release third quarter 2015 financial results before markets open on Thursday, November 5, 2015. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and business highlights.



The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 56415971. A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event for 30 days.



About Minerva Neurosciences:



Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in development for the treatment of schizophrenia; MIN-202 (JNJ-42847922), in development for the treatment of insomnia and adjunctive major depressive disorder (MDD); MIN-117, in development for the treatment of MDD; and MIN-301, in development for the treatment of Parkinson's disease.  Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV." For more information, please visit www.minervaneurosciences.com.  
CONTACT: William B. Boni

         VP, Investor Relations/

         Corp. Communications

         Minerva Neurosciences, Inc.

         (617) 600-7376




This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Minerva Neurosciences, Inc. via Globenewswire

HUG#1961781

News Provided by Acquire Media